Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity of 9-valent HPV Vaccine in Immunocompromised Children
NCT05439083Phase 4Recruiting
- Start
- Mar 2023
- Primary completion
- Sep 2024
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of recombinant human papillomavirus 9-valent vaccine in human papillomavirus infection. Started Mar 2023; status: recruiting.
02
Drugs
recombinant human papillomavirus 9-valent vaccine
03
Conditions
human papillomavirus infection
Beyond the preview
Go deeper on NCT05439083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05439083.